GlassScriptPhysician profile
David L Mcatee
NPI 1841273828
$10,613.51
in general payments reported to CMS, 2019-2025
50 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $917 · 2021: $2,132 · 2022: $1,635 · 2023: $1,601 · 2024: $1,856 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,514.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,645.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,596.40 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,065.05 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $674.12 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $610.79 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $551.25 | 2020-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $545.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $346.47 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Astellas Pharma US INC | $321.08 | 2019-2025 | Veozah |
| Boston Scientific Corporation | $314.54 | 2021-2025 | Watchman Flx |
| Abbott Laboratories | $303.77 | 2021-2025 | Jot Dx, Freestyle Libre 3, Gallant |
| Janssen Pharmaceuticals, INC | $244.66 | 2019-2024 | Xarelto |
| Ibsa Pharma INC. | $203.12 | 2021-2025 | Licart, Tirosint, Flector |
| Merck Sharp & Dohme LLC | $198.31 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Arbor Pharmaceuticals, INC. | $150.98 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcatee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.